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L ipoprotein(a),  or Lp(a),  is a low-density lipopro-tein (LDL)-like particle.  Apolipoprotein B is cova-
lently linked to apolipoprotein(a) by a single disulfide 
bond [1].  Circulating concentrations of Lp(a) vary 
widely across individuals and ethnic subgroups,  medi-
ated in large part by genetic variations at the LPA gene 
locus [2].  A meta-analysis of 126,634 participants in 36 
prospective studies found that Lp(a) was an indepen-
dent risk factor for coronary heart disease and stroke 
[3].  Mendelian randomization studies have linked 
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Lipoprotein(a),  or Lp(a),  is a low-density lipoprotein-like particle largely independent of known risk factors 
for,  and predictive of,  cardiovascular disease (CVD).  We investigated the association between baseline Lp(a) 
levels and the progression of coronary artery calcification (CAC) in patients with hypercholesterolemia under-
going statin therapy.  This study was a sub-analysis of a multicenter prospective study that evaluated the annual 
progression of CAC under intensive and standard pitavastatin treatment with or without eicosapentaenoic acid 
in patients with an Agatston score of 1 to 999,  and hypercholesterolemia treated with statins.  We classified the 
patients into 3 groups according to CAC progression.  A total of 147 patients (mean age,  67 years; men,  54%) 
were analyzed.  The proportion of patients with Lp(a) > 30 mg/dL significantly increased as CAC progressed 
(non-progression; 5.4%,  0 < CAC progression ≦100; 7.7%,  and CAC progression > 100; 23.6%).  Logistic 
regression analysis showed that Lp(a) > 30 mg/dL was an independent predictor of the annual change in 
Agatston score > 100 (OR: 5.51; 95% CI: 1.28-23.68; p = 0.02),  even after adjusting for age,  sex,  hyperten-
sion,  diabetes mellitus,  current smoking,  body mass index,  and lipid-lowering medications.  Baseline Lp(a) 
> 30 mg/dL was a predictor of CAC progression in this population of patients with hypercholesterolemia 
undergoing statin therapy.
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genetic variations at the LPA locus to both circulating 
Lp(a) concentrations and the risk for cardiovascular 
disease (CVD),  supporting a causal role of Lp(a) in 
CVD pathogenesis [4 , 5].  Generic methods to modu-
late circulating Lp(a) concentrations in daily practice 
remain to be determined,  and the further accumulation 
of evidence based on the monitoring of patients with 
high Lp(a) levels (even when undergoing treatment 
with lipid-lowering drugs such as statins) is crucial 
[2 , 6].
Among the methods available for the assessment of 
CVD risk,  coronary artery calcification (CAC),  which 
is determined by computed tomography (CT),  is an 
excellent marker for the clinical measurement of the 
burden of CVD risk [7].  Detrano et al.  reported that the 
adjusted risk for a coronary event increased by a factor 
of 9.67 among participants with CAC scores > 300 com-
pared to participants with no coronary calcification [8].  
After serial assessments,  the progression of CAC scores 
has been proposed as a useful predictor of cardiac out-
come [9-11].
We recently reported the results of a prospective 
multicenter study (Effect of pitavastatin and EPA on 
coronary artery calcification detected by computed 
tomography: PEACH study) that examined the effects 
of intensive and standard pitavastatin treatment with or 
without eicosapentaenoic acid (EPA) on the annual 
progression of CAC [12].  In that study,  we found that 
the overall CAC progression rate over 1 year was 40% 
and that the CAC progression in each patient group was 
not affected by the allocated treatments.  A determina-
tion of the factors involved in CAC progression is of 
interest.
Cross-sectional studies have reported an association 
between Lp(a) and CAC [13 , 14].  Data from a large 
Asian cohort of 14,583 participants suggested a robust 
association between higher Lp(a) level and CAC in both 
men and women,  regardless of LDL cholesterol level 
and other CVD risk factors [14].  However,  that study 
was limited by the nature of cross-sectional studies with 
regard to causality.  Longitudinal studies (including 
short-term studies) are required to confirm the progres-
sion of CAC using baseline Lp(a) levels.  In the present 
study,  we analyzed the association between baseline 
Lp(a) levels and the annual progression of CAC in 
patients with hypercholesterolemia who were undergo-
ing statin therapy.
Methods
Ethical considerations. The principal study was a 
prospective,  open-label,  multicenter trial conducted 
between May 2010 and August 2011.  That study was 
approved by the Ethics Committee of Okayama 
University Graduate School of Medicine,  Dentistry,  
and Pharmaceutical Sciences (Certificate No. 1652) and 
other hospitals involved.  All participants provided 
written informed consent before enrolling.  The study 
was conducted in accord with the principles contained 
within the Declaration of Helsinki.  The study is regis-
tered at the UMIN Clinical Trials Registry 
(UMIN000003171; Effect of pitavastatin and EPA on 
coronary artery calcification detected by computed 
tomography: PEACH study).
Study design. The current study was a pre-speci-
fied sub-analysis of the PEACH study [12].  Eligible 
patients were adults ( > 20 years old) with an Agatston 
score of 1 to 999,  with hypercholesterolemia (LDL cho-
lesterol ≥ 140 mg/dL at screening or taking a statin),  
and no history of CVD.  The exclusion criteria were a 
history of coronary revascularization,  including percu-
taneous coronary intervention and coronary artery 
bypass surgery; Agatston score of 0 or > 1,000; familial 
hypercholesterolemia; use of cyclosporine; and use of 
lipid-lowering agents excluding statins.  Patients were 
enrolled after an evaluation for eligibility at each insti-
tution,  including baseline multi-detector row computed 
tomography (MDCT) image acquisition.  The partici-
pants were randomly allocated into 3 groups: the 
pitavastatin 2 mg/day,  pitavastatin 4 mg/day,  or 
pitavastatin 2 mg/day combined with EPA 1,800 mg/
day groups.  After taking pitavastatin 2 mg/day for 2 
months to check for tolerance,  the allocated treatment 
was started.
Baseline blood test data were obtained just before the 
allocated treatment was started.  MDCT and blood tests 
were performed again at the 1-year follow-up.  Figure 1 
is a flow diagram of the study design.  In the principal 
study,  we enrolled 217 patients at 27 centers in Japan.  
Among them,  157 patients were included in the pri-
mary analysis.  Ten patients were excluded because their 
stored blood samples were not available for the mea-
surement of Lp(a).  A final total of 147 patients were 
included in this post-hoc analysis.  The primary outcome 
of the sub-study was the association between the 
patients’ baseline Lp(a) level and their annual CAC pro-
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gression (Agatston score).
MDCT imaging and CAC analysis. MDCT 
imaging was performed as described [15].  All recruit-
ing sites had previous cardiac CT experience and were 
equipped with 64-slice or higher advanced CT technol-
ogy.  ECG triggering was performed at 80% of the RR 
interval.  MDCT images were documented in a digital 
imaging and communications in medicine (DICOM) 
format,  which was sent to the core laboratory at L&L 
Co.  (Osaka,  Japan) for blinded analysis.  The local sites 
generated the total Agatston score,  which was used as 
the inclusion criterion of this study.  A calcium thresh-
old ≥ 130 Hounsfield units was used.  As described by 
Agatston,  the calcium score was determined by multi-
plying the area of each calcified lesion by a weighing 
factor corresponding to the peak pixel intensity for each 
lesion [16].
The image analysis was performed by a trained 
radiologist and trained cardiologist (Y.K.) who were 
blind to the patients’ data.  Disagreements in data anal-
ysis between the 2 observers were resolved by consen-
sus.  We divided the participants into three groups 
according to the severity of CAC progression over 1 
year: no progression,  0 < CAC progression ≤ 100,  and 
CAC progression > 100.  CAC progression was defined 
as any CAC increase over the year.
Risk factors and laboratory analyses. Data on 
demographics,  smoking status,  and medication were 
collected for each participant.  Current smoking was 
defined as a history of cigarette smoking during the past 
year.  Diabetes was confirmed according to the criteria 
of the American Diabetes Association [17] or based on 
a history of diabetes mellitus treatment.  Hypertension 
was defined as having a seated blood pressure of 
≥ 140/90 mmHg or undergoing treatment with antihy-
pertensive medication.  Body mass index (BMI) was 
calculated as body weight (kg) divided by squared 
height (m).
All laboratory values were determined at an inde-
pendent central study laboratory (SRL,  Tokyo,  Japan).  
Standard enzymatic methods were used to measure 
total cholesterol,  high-density lipoprotein (HDL) cho-
lesterol,  LDL cholesterol,  and triglycerides.  High-
sensitivity C-reactive protein levels were determined 
using an assay (Roche-Hitachi; Hitachi,  Tokyo,  Japan).  
Residual serum was separated and stored at −80°C,  and 
the serum concentration of Lp(a) was measured using 
an enzyme-linked immunosorbent assay (Shino-Test,  
Tokyo,  Japan) [18].
Statistical analysis. Continuous variables are 
mean (standard deviation) or median (25th percentile,  
75th percentile),  as appropriate.  Categorical variables 
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Fig. 1　 Flow diagram of 
patient enrollment.  PIT2,  
pitavastatin 2 mg/day; PIT4,  
pitavastatin 4 mg/day; EPA,  
e i cosapen taeno i c  ac i d 
1,800 mg/day; MDCT,  multi- 
detector row computed tomog-
raphy.
are frequency and proportion (%).  The Kruskal-Wallis 
test was used to compare continuous variables among 
the groups.  The chi-square test was used to compare 
categorical variables.  Pearson’s correlation coefficients 
were used to assess relationships between Lp(a) and 
other parameters.  Data that were not normally distrib-
uted,  as determined by the Kolmogorov-Smirnov test,  
were logarithmically transformed before linear regres-
sion analysis.  Logistic analysis was performed to deter-
mine the odds ratio (OR) with 95% confidence intervals 
(95%CI) for the progression of CAC associated with 
baseline Lp(a) level ( > 30 mg/dL and ≤ 30 mg/dL).  The 
following variables were entered into the logistic model:  
age,  sex,  hypertension,  diabetes mellitus,  current 
smoking,  BMI,  and lipid-lowering medications 
(pitavastatin 2 mg/day,  pitavastatin 4 mg/day,  or 
pitavastatin 2 mg/day combined with EPA 1,800 mg/
day).  A p-value < 0.05 was considered significant.  
Statistical analyses were performed using SPSS 27.0 for 
Windows (IBM,  Armonk,  NY,  USA).
Results
Baseline characteristics. Table 1 summarizes the 
baseline characteristics of participants.  The mean age 
was 67 years,  and 54% were men.  The proportions of 
patients with hypertension and diabetes mellitus were 
81% and 27%,  respectively.  The median baseline Lp(a) 
level was 10.2 mg/dL,  and 9.5% of participants (n = 14) 
had an Lp(a) level > 30 mg/dL.
Association between metabolic parameters and 
baseline Lp(a) levels. A bivariate correlation analysis 
with baseline Lp(a) and other metabolic parameters 
showed that age was positively correlated with the base-
line Lp(a) level,  and the triglycerides level was nega-
tively correlated with the baseline Lp(a) level (Table 2).  
There was no correlation between the baseline Lp(a) 
level and CAC scores.
Comparison of variables according to CAC progres-
sion. At the 1-year follow-up,  110 patients (75%) 
showed CAC progression.  When we compared baseline 
parameters among the groups with no CAC progres-
sion,  0 < CAC progression ≤ 100,  and CAC progression 
> 100,  it was revealed that the proportion of patients 
with diabetes mellitus was significantly increased and 
the LDL cholesterol levels were significantly decreased 
as the severity of CAC progression increased (Table 3).  
The Lp(a) levels in patients with no progression,  
0 < CAC progression ≤ 100,  and CAC progression > 100 
were 11.6 (6.8,  17.2),  8.6 (5.0,  20.3),  and 13.1 (4.1,  
40.4),  respectively,  and did not differ significantly 
among the groups (p = 0.23; Kruskal-Wallis test) 
(Fig. 2A).  The proportion of patients with Lp(a) 
> 30 mg/dL in patients with CAC progression was sig-
nificantly greater than those of the other groups (no 
progression; 5.4%,  0 < CAC progression ≤ 100; 7.7%,  
and CAC progression > 100; 26.3%,  p = 0.03) (Fig. 2B).
Association between baseline Lp(a) and CAC pro-
gression. The logistic analysis showed that the odds 
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Table 1　 Patient characteristics
n＝147
Age (years) 67 (10)
Sex: men,  n (%) 80 (54)
BMI (kg/m2) 25.0 (4.0)
Hypertension,  n (%) 118 (81)
Diabetes mellitus,  n (%) 39 (27)
Current smoking,  n (%) 22 (15)
Lp(a) (mg/dL) 10.2 (5.0,  21.3)
Hemoglobin A1c (%) 5.7 (0.7)
Triglycerides (mg/dL) 117 (89,  165)
LDL cholesterol (mg/dL) 93.6 (24.3)
HDL cholesterol (mg/dL) 55.5 (13.7)
Serum creatinine (mg/dL) 0.77 (0.68,  0.90)
hsCRP (mg/L) 0.054 (0.031,  0.106)
Agatston score 96 (25,  244)
Data are mean (std.  dev.),  number (%),  or median (25th,  75th 
percentiles),  as appropriate.  Lp(a),  lipoprotein a; LDL,  low-density 
lipoprotein; HDL,  high-density lipoprotein; hsCRP,  high-sensitivity 
C-reactive protein.
Table 2　 Correlation between baseline Lp(a)＊ and other parame-
ters
r p-value
Age 0.281 0.001
BMI －0.106 0.208
Fasting blood glucose －0.178 0.033
Hemoglobin A1c －0.06 0.530
Total cholesterol －0.021 0.804
Triglycerides＊ －0.218 0.008
HDL cholesterol 0.06 0.492
LDL cholesterol －0.009 0.915
Serum creatinine －0.089 0.287
hsCRP＊ 0.015 0.853
Agatston score＊ 0.124 0.136
＊Lp(a),  triglycerides,  hsCRP,  and Agatston score were log-trans-
formed.
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Table 3　 Comparison of variables among patients with CAC progression over a 1-year period
No progression
(n＝37)
0＜CAC progression≤100
(n＝91)
CAC progression＞100
(n＝19)
p-value
Age (years) 66.3 (9.4) 67.1 (10.2) 68.7 (7.1) 0.68
Sex: men,  n (%) 20 (54) 45 (49) 15 (79) 0.06
BMI (kg/m2) 25.9 (4.7) 24.9 (3.7) 23.9 (3.4) 0.26
Diabetes mellitus,  n (%) 8 (22) 21 (23) 10 (53) 0.02
Hypertension,  n (%) 30 (81) 74 (81) 14 (74) 0.74
Current smoking,  n (%) 8 (22) 12 (13) 2 (11) 0.41
Systolic BP (mmHg) 134.7 (21.5) 131.0 (16.5) 131.8 (19.8) 0.68
Diastolic BP (mmHg) 76.4 (12.9) 74.4 (10.8) 73.5 (10.8) 0.74
Hemoglobin A1c (%) 5.7 (0.6) 5.7 (0.7) 6.0 (1.0) 0.26
Total cholesterol (mg/dL) 182.8 (30.9) 175.9 (30.9) 166.5 (31.6) 0.23
LDL cholesterol (mg/dL) 101.4 (24.5) 93.1 (22.7) 80.7 (26.8) 0.01
Triglycerides (mg/dL) 123 (92,  128) 108 (84,  165) 141 (89,  155) 0.63
HDL cholesterol (mg/dL) 53.5 (12.4) 56.4 (14.6) 54.8 (11.5) 0.70
Serum creatinine (mg/dL) 0.78 (0.69,  0.86) 0.78 (0.63,  0.90) 0.76 (0.71,  0.98) 0.68
hsCRP (mg/dL) 0.054 (0.034,  0.123) 0.051 (0.025,  0.105) 0.070 (0.038,  0.115) 0.58
Data are mean (std.  dev.),  number (%),  or median (25th,  75th percentiles),  as appropriate.
Table 4　 Odds ratios (95% conﬁdence intervals) for coronary artery calciﬁcation progression ＞100 according to baseline Lp(a) levels
Model 1 Model 2 Model 3 Model 4
Lp(a) ≤30 mg/dL Reference Reference Reference Reference
Lp(a) ＞30 mg/dL 4.72 (1.39-16.08),  p＝0.01 6.84 (1.90-32.16),  p＜0.01 5.59 (1.31-23.81),  p＝0.01 5.51 (1.28-23.68),  p＝0.02
Model 1,  no adjustment: Model 2,  adjusted for age and sex: Model 3,  Model 2＋hypertension,  diabetes mellitus,  current smoking,  and 
BMI: Model 4,  Model 3＋lipid-lowering medications.
Fig. 2　 Comparison of lipoprotein (Lp(a)) 
levels (A) and the proportion of patients with 
high Lp(a) (B) among the groups classiﬁed by 
coronary artery calciﬁcation (CAC) progres-
sion severity over 1 year.
ratio of natural log-transformed Lp(a) for the annual 
progression of CAC >100 was not significant (OR: 1.49,  
95%CI: 0.88-2.53,  p = 0.13).  When the risk for annual 
CAC progression > 100 according to baseline Lp(a) level 
higher or lower than 30 mg/dL was calculated (Table 4),  
the patients with an Lp(a) level > 30 mg/dL showed a 
significantly increased risk for CAC progression com-
pared to the patients with an Lp(a) level ≤ 30 mg/dL in 
the crude model (OR: 4.72,  95%CI: 1.39-16.08;  
Model 1) and after adjusting for all confounding vari-
ables (OR: 5.51,  95%CI: 1.28-23.68; Model 4).
Discussion
This study is the first to report an association 
between the baseline Lp(a) level and CAC progression 
over a 1-year follow-up in patients with hypercholester-
olemia and undergoing statin therapy.  Patients with 
CAC progression > 100 over the 1-year follow-up 
showed a greater proportion of high baseline Lp(a) 
compared to those who had no progression or CAC 
progression < 100 with LDL cholesterol lower than 
100 mg/dL with statin therapy.  The logistic analysis 
revealed that a baseline Lp(a) level > 30 mg/dL pre-
sented a 6.84-fold increased risk for CAC progression 
> 100 compared to the Lp(a) levels ≤ 30 mg/dL.
Our present findings are considered complementary 
to a recent sub-analysis of the JUPITER (Justification 
for the use of statin in prevention: An intervention trial 
evaluating rosuvastatin) trial,  which reported that 
higher Lp(a) concentrations were associated with an 
increased risk for CVD events under statin therapy [19].  
That sub-analysis reported that rosuvastatin reduced the 
incidence of CVD with no interaction which baseline 
Lp(a) levels.  In the present study,  the LDL cholesterol 
levels in the patients with CAC progression > 100 were 
lower than those in the patients with CAC progression 
≤ 100.  Taken together,  our findings suggest that the 
Lp(a) level may be a significant risk factor for CVD 
events in people with a low LDL cholesterol level 
undergoing statin therapy.  This suggestion also has 
important clinical implications with regard to assess-
ments (for instance,  using CAC) used to identify 
patients with a high Lp(a) level.  This is because generic 
methods for modulating circulating Lp(a) concentra-
tions in daily practice remain to be determined,  and 
careful monitoring of patients with a high Lp(a) level is 
needed.
In terms of a clinical cutoff point for Lp(a),  the 2016 
Canadian Cardiovascular Society Guidelines for the 
Management of Dyslipidemia consider Lp(a) >30 mg/dL 
to be a risk factor,  and those guidelines suggest mea-
suring Lp(a) to inform decision-making,  particularly in 
patients at intermediate risk and those with a family 
history of premature CAD,  and in younger patients 
[20].  A large meta-analysis showed an inflection for risk 
of myocardial infarction at Lp(a) > 30 mg/dL [3].  Data 
from the Multi-Ethnic Study of Atherosclerosis (MESA) 
reported that cutoff values of Lp(a) for identifying the 
risk of CVD events differ among races,  from 30 mg/dL 
to 50 mg/dL [21].  Tsimikas reported that Lp(a) levels 
are skewed leftward,  and most individuals (approx.  
70%) have values in the normal range of < 30 mg/dL 
[22].
In the present study,  the median Lp(a) value was 
10.2 mg/dL,  and the proportion of patients with Lp(a) 
> 30 mg/dL and > 40 mg/dL were 9.5% and 3.4%,  
respectively.  Considering these results,  we used Lp(a) 
> 30 mg/dL as the cutoff value for the high Lp(a) level,  
and we observed that high Lp(a) was a significant risk 
factor for CAC progression.  However,  the appropriate 
cutoff value for Asian populations should be deter-
mined by further studies.
The mechanisms underlying the association between 
elevated Lp(a) and the development of CAC remain 
unclear.  Elevated Lp(a) may lead to atherosclerosis 
when particles become trapped within the arterial 
intima,  and may also serve as a carrier of oxidized 
phospholipids by apolipoprotein B 100,  which may 
propagate atherosclerosis via inflammatory pathways 
[23].  In addition,  it was reported that Lp(a) and oxi-
dized phospholipids mediate macrophage apoptosis in 
endoplasmic reticulum-stressed macrophages by signal-
ing through the CD36/Toll-like receptor 2 pathway [24].  
We thus speculate that Lp(a) may contribute to CAC 
through the development of atherosclerosis via multiple 
pathways.
In this study,  the patients with baseline Lp(a) 
> 30 mg/dL showed a significantly increased risk for 
CAC progression with low LDL cholesterol and under-
going statin therapy.  CAC incidence and progression is 
considered an excellent surrogate marker for the pre-
diction of CVD risk [7].  A cross-sectional study of an 
Asian population reported that Lp(a) levels were posi-
tively associated with CAC score [14].  However,  that 
was a cross-sectional study and it therefore could not 
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show a causal relationship between Lp(a) and CAC pro-
gression.  Recent data from a health checkup program 
suggest that people with a baseline Lp(a) level ≥ 50 mg/
dL have a 1.33-fold increased risk for CAC progression 
compared to those with an Lp(a) level < 50 mg/dL [25].  
The present study is the first longitudinal study to eval-
uate the association between baseline Lp(a) and CAC 
progression in patients with hypercholesterolemia 
undergoing statin therapy.
This study has several limitations.  First,  as the study 
was of people with hypercholesterolemia undergoing 
statin therapy,  the results cannot be applied to the gen-
eral population.  Second,  although the Agatston score as 
a marker for quantifying CAC is an excellent surrogate 
marker for the prediction of CVD,  we analyzed only 
CAC progression as the endpoint,  not actual CVD 
events.  We thus cannot conclude that there is an asso-
ciation between high Lp(a) and CVD events.  Third,  the 
duration of follow-up was 1 year,  and a longer fol-
low-up period might reveal a difference in the impact of 
Lp(a) on the progression of CAC.  In addition,  data on 
coronary CT angiography were not available in this 
study.  Fourth,  changes in plaque volumes and mor-
phology could not be evaluated.  Finally,  the relation-
ship between the change in Lp(a) and the change in 
CAC remains unclear.  Prospective studies for evaluat-
ing the effect of lowering Lp(a) on the progression of 
CAC are warranted to address this issue.
In,  conclusion,  high Lp(a) played a role in CAC 
progression in this population of patients with hyper-
cholesterolemia undergoing statin therapy.  Our find-
ings suggest that measuring Lp(a) levels will help in the 
risk assessment for CVD events as well as treatment 
options.
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